RT Journal Article
SR Electronic
T1 Hospital-Based Donor Recruitment and Pre-Donation Serologic Testing for COVID-19 Convalescent Plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.20.20158048
DO 10.1101/2020.07.20.20158048
A1 Balcerek, Joanna
A1 Trejo, Evelin
A1 Levine, Kendall
A1 Couey, Paul
A1 Kornberg, Zoe V.
A1 Rogine, Camille
A1 Young, Charlotte
A1 Li, Jonathan
A1 Shy, Brian R.
A1 Taylor, Jordan E.
A1 Bakhtary, Sara
A1 Friedlander, Terence
A1 Lynch, Kara L.
A1 Bern, Caryn
A1 Esensten, Jonathan H.
YR 2020
UL http://medrxiv.org/content/early/2020/07/25/2020.07.20.20158048.abstract
AB Background Major blood centers perform serologic testing on potential COVID-19 convalescent plasma donors retrospectively after blood donation. A hospital-based recruitment program for COVID-19 convalescent plasma (CCP) donors may be an efficient way to prospectively identify potential donors.Study Design and Methods Patients who recovered from known or suspected COVID-19 were identified and recruited through medical record searches and public appeals. Participants were screened with a modified donor history questionnaire (DHQ), and if eligible, were consented and tested for SARS-CoV-2 antibodies (IgG and IgM). Participants who were positive for SARS-CoV-2 IgG were referred to a local blood center for convalescent plasma collection.Results Of 179 individuals screened, 128 completed serologic testing and 89 were referred for convalescent plasma donation to a local blood center (49.7% of those screened). IgG antibodies to SARS-CoV-2 were detected in 23/51 (45.1%) of participants with suspected COVID-19 and in 66/77 (85.7%) of participants with self-reported PCR-confirmed COVID-19. Testing was performed at a median of 38 days since last symptoms. Participant age positively correlated with anti-SARS-CoV-2 IgG and IgM levels. Time since last symptoms did not correlate with IgG or IgM levels. A wide range of SARS-CoV-2 IgG levels were observed.Conclusion A hospital based CCP donor recruitment program can prospectively identify potential CCP donors. Variability in SARS-CoV-2 IgG levels has implications for selection of CCP units for transfusion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Departments of Laboratory Medicine and Division of Hematology & Oncology, Zuckerberg San Francisco General Hospital, University of California, San Francisco.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received UCSF Institutional Review Board approval on 4/17/2020 (#20-30637).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author JE.